Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
REVIEW
Stage IIIA NSCLC with limited N2 disease: Ιnduction chemotherapy and reseption or surgical treatment and adjuvant chemotherapy?
| 1 | Thoracic Surgery Clinic, Hospital for Diseases of the Chest “SOTIRIA” |
| 2 | 4th Department of Pneumonology, Hospital for Diseases of the Chest “SOTIRIA” |
| 3 | Nursing Department, Hospital for Diseases of the Chest “SOTIRIA” |
| 4 | Oncology Unit, 3rd Department of Athens School of Medicine, Hospital for Diseases of the Chest “SOTIRIA” |
Pneumon 2015;28(1):87–94
KEYWORDS
REFERENCES (46)
1.
Siegel R, Naishadham D, Jemal A. Cancel statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3.
van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and MIA. Chest 2000;117:374-379.
4.
Fang D, Zhang D, Huang G, Zhang R, Wang L, Zhang D. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Ann Thorac Surg 2001;72:1155-1159.
5.
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
6.
Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
7.
Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
8.
Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
9.
Depierre A, Milleron B, Moro-Sibilot D, et al; French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIia non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
10.
Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611.
11.
Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2008;3.S56(Abstr 1500).
12.
Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005;26:192-197.
13.
Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
14.
De Marinis F, Nelli F, Migliorino MR, et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage HIA(N2) non-small cell lung carcinoma: a Phase II multicenter study. Cancer 2003;98:1707-1715.
15.
O’ Brien ME, Splinter T, Smit EF, et al, EORTC Lung Cancer Group. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer, an EORTC phase II stydy (EORTC 08958). Eur J Cancer 2003;39:1416-1422.
16.
Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage HIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. Cancer 2003;98:128-134.
17.
Biesma B, Manegold C, Smit H J, et al; EORTC Lung Cancer Group. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization foe research and treatment of cancer (EORTC 08984). Eur J Cancer 2006; 42:1399-1406.
18.
Garrido P, Gonzalez-Larrida JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and HIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736-4742.
19.
Berghmas T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
20.
Grunenwald DH, Albain KS. The potential role of surgery after induction treatment. Semin Radiat Oncol 2004;14:335-339.
21.
Doddoli C, Barlesi F, Trousse D, et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005;130:416-425.
22.
Van Schil P, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005;26:192-197.
23.
Fernando HC, Goldstraw P. The accuracy of clinical evaluative intrathoracic staging. Cancer 1990;65:2503-2506.
24.
Ginsberg RJ. Multimodality therapy for stage NIA (N2) lung cancer: an overview. 1993;103:356S-359S.
25.
Van Klaveren RJ, Often HG, Cox AL, et al. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993; 56:300-304.
26.
Watanabe Y, Shimizu J, Hayashi Y, et al. Results of surgical treatment on patients with stage MA non-small cell Lung cancer. J Thorac Cardiovasc Surg 1991;39:44-49.
27.
Maggi GC, Mancuso M, Oliaro A, et al. Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg 1990; 75:17-21 (27L).
28.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899-909.
29.
Scagliotti GV, Fossati R, Torri V, et al; Adjuvant Lung Project Italy/Eyropean Organization for Research Treatment of CancerLung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II or MA non-small-cell Lung cancer. J Natl Cancer Ins 2003;95:1453-1461.
30.
Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small-cell Lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
31.
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell Lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]: a randomized controlled trial. Lancet Oncol 2006;7:719-727.
32.
Le Chevalier T, Dunant A, Arriagada R, et al, IALT Collaborative Group. Long-term results of the international Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer (NSCLC). J Clin Oncol 2008; 26: (May 20 suppl;abstr 7507).
33.
Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552- 3559.
34.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
35.
Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators. Vinorelbine plus cisplatin vs.
36.
Solomon B, Bunn PA Jr. Adjuvant chemotherapy for non-smallcell lung cancer. Cancer Invest 2007;25:217-225.
37.
Strauss GM, Herndon J, Maddaus MA, et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxei and carboplatin following resection in Stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22:7019.
38.
Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138.
39.
Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006.
40.
Stewart LA, Burdett S, Tierney JF, et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small-cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25:7552.
41.
Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable in non-small-cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet2007; 369:1929-1937.
42.
Potti A, Mukherjee S, Petersen R, et al. Agenomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
43.
Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-3226.
44.
Ju Z, Kapoor M, Newton K, et al. Global detection of molecular changes reveals concurrent alteration of several biological pathways in non-small-cell lung cancer cells. Mol Genet Genomics 2005; 274:141-154.
45.
13th World Conference on Lung Cancer (WCLC): Abstact PRS.3. Presented August 3, 2009.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.